ALAMEDA, Calif.--(BUSINESS WIRE)--Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced its participation in the 27th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place at the Baltimore Convention Center in Baltimore, MD, and virtually from May 7-11, 2024.
Scribe will deliver two oral presentations and one poster presentation showcasing the latest developments in its CRISPR X-Editor (XE) and Epigenetic Long-Term X-Repressors (ELXR) technologies enabled by its CRISPR by Design™ approach. The company’s presentations will include data demonstrating the potent editing activity of XE in non-human primates, the potential for XE to address P23H.RHO-related autosomal dominant retinitis pigmentosa (adRP), and the comprehensive engineering approach to creating highly potent ELXRs.
More details on each presentation are listed below and the full abstracts are available on the ASGCT meeting website.
Oral presentation title: AAV-Mediated Delivery of a Novel CasX-Editor Molecule Achieves Allele-Specific and Potent Editing of P23H Rhodopsin in a Mouse Model of Retinitis Pigmentosa
Abstract number: 180
Session title: Ophthalmic and Auditory: Disease Focus
Date: Thursday, May 9, 2024
Time: 2:15 - 2:30 p.m. ET
Location: Room 318-323
Speaker: Cécile Fortuny, Ph.D., Senior Scientist II at Scribe
Oral presentation title: Engineering CasX to Create a Gene Editor with Potent Activity in Non-Human Primates
Abstract number: 155
Session title: Gene Disruption and Excision
Date: Thursday, May 9, 2024
Time: 2:55 - 3:12 p.m. ET
Location: Ballroom 3
Speaker: Addison Wright, Ph.D., Principal Scientist at Scribe
Poster title: Comprehensive Engineering of a CasX-Based Repressor to Create Highly Potent Epigenetic Editors
Abstract number: 1670
Session title: Epigenetic Editing and RNA Editing
Date: Friday, May 10, 2024
Time: 12:00 - 7:00 p.m. ET
Location: Exhibit Hall
Speaker: Jason Fernandes, Ph.D., Principal Scientist at Scribe
About Scribe Therapeutics
Scribe Therapeutics is revolutionizing the development of optimized in vivo CRISPR-based genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases. Our CRISPR by Design™ approach engineers bacterial immune systems into a premier suite of genome editing tools built for unique molecular advantages in activity, specificity and deliverability that translate into safer and more effective genetic therapies. Co-founded by Nobel Prize winner Jennifer Doudna and backed by leading life sciences investors, Scribe is engineering the future of genetic medicine. To learn more, visit www.scribetx.com.
